Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
ALL
•
Hematology
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
Related Questions
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
What experience have you had with familial clustering of polycythemia vera?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
How would you proceed for a patient who has completed therapy for classic Hodgkin lymphoma with overall great disease response, but with new FDG avid lymph node on PET that is not amenable to biopsy?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
